PHARVARIS N V's ticker is PHVS and the CUSIP is N69605108. A total of 22 filers reported holding PHARVARIS N V in Q3 2023. The put-call ratio across all filers is - and the average weighting 4.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $28,413,670 | +92.8% | 1,361,460 | +39.8% | 1.66% | +100.6% |
| Q2 2023 | $14,740,516 | +224022.2% | 973,614 | +19.2% | 0.83% | +90.8% |
| Q1 2023 | $6,577 | -28.4% | 816,460 | 0.0% | 0.43% | -29.6% |
| Q4 2022 | $9,185 | -99.9% | 816,460 | -32.4% | 0.62% | -4.9% |
| Q3 2022 | $9,262,000 | -63.4% | 1,207,500 | +5.4% | 0.65% | -66.2% |
| Q2 2022 | $25,326,000 | +103.9% | 1,145,953 | +67.3% | 1.92% | +100.7% |
| Q1 2022 | $12,420,000 | +25.1% | 684,888 | -0.7% | 0.95% | +61.7% |
| Q4 2021 | $9,925,000 | -18.8% | 689,731 | 0.0% | 0.59% | +18.7% |
| Q3 2021 | $12,229,000 | -10.3% | 689,731 | -7.4% | 0.50% | +7.3% |
| Q2 2021 | $13,634,000 | -42.7% | 744,863 | -13.8% | 0.46% | -12.6% |
| Q1 2021 | $23,811,000 | – | 864,143 | – | 0.53% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 3,743,450 | $56,675,833 | 27.86% |
| venBio Partners LLC | 4,264,672 | $64,567,134 | 23.37% |
| Bain Capital Life Sciences Investors, LLC | 4,868,784 | $73,713,390 | 7.59% |
| VR Adviser, LLC | 1,326,200 | $20,078,668 | 3.21% |
| 5AM Venture Management, LLC | 587,600 | $8,896,264 | 2.22% |
| Novo Holdings A/S | 1,329,325 | $20,125,981 | 1.56% |
| GENERAL ATLANTIC, L.P. | 4,406,252 | $66,710,655 | 1.05% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 200,000 | $3,028,000 | 0.94% |
| Cormorant Asset Management, LP | 973,614 | $14,740,516 | 0.83% |
| Soleus Capital Management, L.P. | 391,900 | $5,933,366 | 0.66% |